OncoOne

New First Disclosure: Pretargeted Radioimmunotherapy with the Novel Anti-oxMIF/HSG Bispecific Antibody ON105 Results in Significant Tumor Regression in Murine Models of Cancer. bit.ly/3VkAas3 @OncoOne #openaccess

Would you like to learn more about @OncoOne's current licensing and partnering prospects related to our Anti-oxMIF and PreTarg-it® platforms? Meet us at #BioEurope2023 in Munich next week to discover more.

Join us at #FestivalofBiologics in Basel next week! Catch our CSO Michael Thiele's presentation on "Antibody ON104: Tackling Inflammation by targeting oxMIF." Visit poster #76 to see ON104's effectiveness in a mouse arthritis model by Senior Scientist Maroua Ferhat. See you there

We are thrilled to present our newsletter for the second quarter of 2023, featuring updates on all our anti-oxMIF programs. Click the link mailchi.mp/98b9e3f15da8/o… to access the newsletter or visit our website oncoone.com. Stay informed and stay connected!

We are delighted to welcome Stephanie Spach, MSc, as the newest member of the @OncoOne team, joining us on July 1st. Stephanie will be a valuable addition as a Research Associate in our Biology Team. We are excited to work together towards our common goals.

🎉Celebrate with us! @OncoOne turns 5, reflecting on remarkable achievements. €18M funding, 2 optimized anti-oxMIF antibodies (ON203 for cancer, ON104 for inflammation) reaching Phase I readiness and our innovative PreTarg-it Platform. Grateful for our talented and diverse team!

Exciting News! @OncoOne recognized as a Minicorn by @Tracxn Soonicorn Awards! Proud to be among Austria's top tech startups. This prestigious award highlights our potential to become a Unicorn, defined by its valuations surpassing one billion dollars in their latest funding.

🌟 Exciting News! Our VP Christine Landlinger-Schubert will present at #ERA2023 Congress in Milan. Her talk on "ON104: A novel bioengineered antibody targeting oxMIF ameliorates experimental Glomerulonephritis" is scheduled for June 16, 12-13:15 CEST.

Delighted to announce Friedmund Bachmann’s promotion to VP CMC at @OncoOne, effective April 1, 2023! With a remarkable career spanning renowned companies, Friedmund brings expertise in Pharma Sciences and CMC. Congrats, Friedmund!

Exciting news! @OncoOne's CEO, Randolf Kerschbaumer, will be attending #BIO2023 in Boston from June 5-8! We're eager to connect with like-minded companies and advance our research in oncology and inflammation. Let's collaborate and innovate together! See you there!

Thrilled to announce the promotion of Christine Landlinger-Schubert to VP Preclinical & Translational R&D at OncoOne! With 15 years of biotech experience, she's shown exceptional leadership skills and her expertise will undoubtedly play a pivotal role in driving OncoOne's success

Join @OncoOne's CTO Alexander Schinagl at #PEGS23 Boston for his talk "Pretargeted Radioimmunotherapy with an Anti-oxMIF/HSG Bispecific Antibody Demonstrates Efficacy in Murine Models of Cancer" today from 5:30 to 6:00 PM (ET) in Ballroom A. #oxMIF #PreTargit #radioimmunotherapy

Join OncoOne at #AAI2023 for Maroua's talk on "ON104, a novel antibody targeting oxMIF, showing efficacy in preclinical models of chronic inflammation" in the Block Symposium 184 from 3:45-5:45 PM ET in Room 206. Don't miss it!

Discover @OncoOne's latest research on oxMIF targeting anti-inflammation therapies at #AAI2023. Join us for Maroua's presentation on ON104, a novel antibody targeting oxMIF, at Poster #P958 in the Exhibition Hall from 2:30 PM - 3:45 PM ET.

Exciting news! @OncoOne's CSO Michael Thiele will be attending #BIOEQUITY in Dublin from May 14-16. Schedule a 1:1 meeting with Michael using the conference partnering tool to learn more about our oxMIF targeted pipeline for cancer and inflammation. Don't miss out!

Proud to announce our team at @OncoOne achieved an important milestone! Our first research article, "Preclinical Evaluation of #ON203," is now published in @MCT_AACR's May issue and selected by editors as a First Disclosure. Check out our cover art! aacrjournals.org/mct/issue/22/5

Excited to share OncoOne’s latest research on " Pretargeted Radioimmunotherapy with an Anti-oxMIF/HSG Bispecific Antibody Demonstrates Efficacy in Murine Models of Cancer " which will be presented by our CTO Alexander Schinagl at #PEGS23. Join him on Tuesday May 16 for his talk.

Meet @OncoOne at #IMMUNOLOGY2023 in Washington DC! Join us to listen to Maroua's talk on our novel antibody ON104 targeting oxidized macrophage migration inhibitory factor (#oxMIF) & meet us at our poster #860. See you on May 12th & 13th! #immunology #inflammation #AAI2023

Very busy day for our CTO Alexander Schinagl at our poster at #AACR23 today presenting the latest ON203 data, OncoOne‘s lead anti-oxMIF mAb.

Exciting news! OncoOne's 1st research article "Preclinical Evaluation of ON203, A Novel Bioengineered mAb Targeting Oxidized MIF as an Anticancer Therapeutic" was published online (aacrjournals.org/mct/article/do…) in Molecular Cancer Therapeutics @MCT_AACR TODAY!